The recent case of an 8-year-old boy who experienced a remarkable recovery from a rare disease highlights the potential of an experimental compound developed by researchers at NYU Langone Health. The boy, initially wheelchair-bound due to worsening paralysis, was able to walk and run again after receiving treatment with the compound.
This breakthrough study, published in the journal Nature on July 9, focuses on mitochondria and their role in energy production. The boy suffered from HPDL deficiency, a condition that disrupts the synthesis of Coenzyme Q10 (CoQ10), leading to severe symptoms like paralysis and fatigue.
The experimental treatment was based on findings from a 2021 study led by Dr. Robert Banh under the guidance of Dr. Michael E. Pacold at NYU Grossman School of Medicine. The research demonstrated that CoQ10 precursors could restore mitochondrial function and reverse related brain damage in animal models.
When approached by the child’s parents, NYU Langone pediatric neurologists Dr. Claire Miller and Dr. Giulietta M. Riboldi collaborated with a team to obtain government authorization for treating the boy with 4-HB, one of these precursors. The results were significant, with noticeable improvements in the child’s condition within two months.
Dr. Pacold noted this was “the first demonstration” that neurological symptoms of primary CoQ10 deficiency can be improved by using its smaller precursors instead of CoQ10 itself.
While promising for rare diseases like HPDL deficiency, this research also has broader implications for conditions such as heart disease and Alzheimer’s, where CoQ10 levels are known to decrease with age.
Further studies will aim to determine optimal treatment windows and dosages for broader application. Meanwhile, NYU Langone is looking to license this innovative approach for further development.
